TP53 and cancer: There were missing data in education level (5.3%), stage of disease (10.1%), grade of cancer (41.5%), estrogen receptor (ER) (38%), progesterone receptor (PR) (38.7%), Her2 (47.6%), P53 (74.7%), pathology report (14.3%), lymph nodes involvement (17.1%), tumor size (29.1%), type of surgery (16.6%), chemotherapy (22.9%), radiotherapy (29.2%), and hormone therapy (46%).